Publishing of Orion Corporation's Interim Report for January-September 2017 on 26 October 2017
(Thomson Reuters ONE) -
ORION CORPORATION PRESS RELEASE 12 OCTOBER 2017 at 10.30 A.M. EEST
Publishing of Orion Corporation's Interim Report for January-September 2017 on
26 October 2017
Orion will publish its Interim Report for January-September 2017 on Thursday,
26 October 2017 approximately at 12.00 noon Finnish time (EEST). The release and
related presentation material in Finnish and in English will be available on the
Group's homepage at www.orion.fi/investors promptly after the publishing.
News conference for analysts and media
A news conference for analysts and media will be held on Thursday, 26 October
2017 at 13.30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki.
President and CEO Timo Lappalainen will give a brief presentation in English on
the financial review. Questions can be asked after the presentation also via
teleconference.
Participants should be prepared to present a photo ID on request.
Live webcast and conference call
A link to the live webcast will be available on Orion's website at
www.orion.fi/investors.
The conference call ID is 5626925 and the phone numbers to participate the
conference are:
Finland: +358 (0)9 7479 0404
Sweden: +46 (0)8 5065 3942
UK: +44 (0)330 336 9411
USA: +1 719-457-1036
News conference recordings
A recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on Orion's website later the same
day.
Silent period
The silent period preceding the publication is ongoing and continues until the
disclosure.
Contact person:
Lilli Riikonen, Communications Manager, tel. +358 10 426 2319
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish pharmaceutical company - a builder of
well-being. Orion develops, manufactures and markets human and veterinary
pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The
company is continuously developing new drugs and treatment methods. The core
therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS)
disorders, oncology and respiratory for which Orion developes inhaled Easyhaler®
pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the
company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq
Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 12.10.2017 - 09:30 Uhr
Sprache: Deutsch
News-ID 563405
Anzahl Zeichen: 3230
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 156 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Publishing of Orion Corporation's Interim Report for January-September 2017 on 26 October 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
